- Home
- Publications
- Publication Search
- Publication Details
Title
Vismodegib
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume 48, Issue 1, Pages 99-106
Publisher
SAGE Publications
Online
2014-01-22
DOI
10.1177/1060028013506696
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study.
- (2017) Deirdre Jill Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: A Report of 2 Cases
- (2013) Sumaira Aasi et al. JAMA Dermatology
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas
- (2012) Marcel Kool et al. ACTA NEUROPATHOLOGICA
- Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
- (2012) Anne Lynn S. Chang et al. ARCHIVES OF DERMATOLOGY
- Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer
- (2012) Jeong In Yun et al. ARCHIVES OF PHARMACAL RESEARCH
- Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
- (2012) Richard A. Graham et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors
- (2012) Glen J. Weiss et al. CANCER
- Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug–drug interaction potential
- (2012) Patricia M. LoRusso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
- (2012) S. B. Kaye et al. CLINICAL CANCER RESEARCH
- A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
- (2012) J. Berlin et al. CLINICAL CANCER RESEARCH
- Daily Dosing of Vismodegib to Steady State Does Not Prolong the Qtc Interval in Healthy Volunteers
- (2012) Richard A. Graham et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
- (2012) Jean Y. Tang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
- (2012) Aleksandar Sekulic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hedgehog Fights Back: Mechanisms of Acquired Resistance against Smoothened Antagonists
- (2011) C. Metcalfe et al. CANCER RESEARCH
- Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
- (2011) R. A. Graham et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic Dose-Scheduling Study of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
- (2011) H. Wong et al. CLINICAL CANCER RESEARCH
- A Single Dose Mass Balance Study of the Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Humans Using Accelerator Mass Spectrometry
- (2011) R. A. Graham et al. DRUG METABOLISM AND DISPOSITION
- Identification, Characterization, and Implications of Species-Dependent Plasma Protein Binding for the Oral Hedgehog Pathway Inhibitor Vismodegib (GDC-0449)
- (2011) Anthony M. Giannetti et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sonic Hedgehog Acts as a Negative Regulator of β-Catenin Signaling in the Adult Tongue Epithelium
- (2010) Fabian T. Schneider et al. AMERICAN JOURNAL OF PATHOLOGY
- Incidence Estimate of Nonmelanoma Skin Cancer in the United States, 2006
- (2010) Howard W. Rogers et al. ARCHIVES OF DERMATOLOGY
- Clinical Experience With Hedgehog Pathway Inhibitors
- (2010) Jennifer A. Low et al. JOURNAL OF CLINICAL ONCOLOGY
- GDC-0449—A potent inhibitor of the hedgehog pathway
- (2009) Kirk D. Robarge et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
- (2009) Charles M. Rudin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
- (2009) R. L. Yauch et al. SCIENCE
- Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
- (2009) Suzie J. Scales et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor
- (2009) H. Wong et al. XENOBIOTICA
- Transient Inhibition of the Hedgehog Pathway in Young Mice Causes Permanent Defects in Bone Structure
- (2008) Hiromichi Kimura et al. CANCER CELL
- Nevoid basal cell carcinoma syndrome (Gorlin syndrome)
- (2008) Lorenzo Lo Muzio Orphanet Journal of Rare Diseases
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search